Skip to content
Screener

Veracyte VCYT Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Biodesix, Inc. logo
Biodesix, Inc.BDSX
$6.41M-10.4%
Natera, Inc. logo
Natera, Inc.NTRA
$49.99M+21.6%
Myriad Genetics logo
Myriad GeneticsMYGN
Castle Biosciences logo
Castle BiosciencesCSTL
Personalis, Inc. logo
Personalis, Inc.PSNL
Guardant Health logo
Guardant HealthGH

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.8B+68.9%
Enterprise value$3.57B+72.0%
P/E43.1×-42.2×
P/S+2.3×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemMarch 31, 2026December 31, 2025
Intangible assets, net85,86389,148
Goodwill767,154767,154
Restricted cash1,6571,648
Other assets1,034902
Total assets$1,436,400$1,406,019
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$6,908$4,593

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's deferred tax assets and other non-current assets?
Veracyte (VCYT) reported deferred tax assets and other non-current assets of $1.03M in Q1 2026.
How has Veracyte's deferred tax assets and other non-current assets changed year-over-year?
Veracyte's deferred tax assets and other non-current assets decreased by 85.4% year-over-year, from $7.1M to $1.03M.
What is the long-term trend for Veracyte's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Veracyte's deferred tax assets and other non-current assets has grown at a -8.4% compound annual growth rate (CAGR), from $1.4M to $902K.

Ask your AI about Veracyte's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude